Orchid Pharma Limited (NSE:ORCHPHARMA)
979.05
-29.20 (-2.90%)
Jun 19, 2026, 3:29 PM IST
Orchid Pharma Stock Forecast
Stock Price Forecast
According to 3 analysts polled by S&P Global, Orchid Pharma stock has a consensus rating of "Strong Buy" and an average price target of ₹976.00. The average 1-year stock price forecast is 0.31% lower than the current stock price, while the lowest is ₹900.00 (-8.07%) and the highest is ₹1,083 (+10.62%).
Price Target: ₹976.00 (-0.31%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Orchid Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Jan '26 | Feb '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Financial Forecast
Revenue This Year
12.89B
from 8.11B
Increased by 58.81%
Revenue Next Year
19.34B
from 12.89B
Increased by 50.08%
EPS This Year
32.10
from 5.35
Increased by 500.48%
EPS Next Year
40.10
from 32.10
Increased by 24.92%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is INR.
Revenue Forecast
| Revenue | 2027 | 2028 |
|---|---|---|
| High | 12.9B | |
| Avg | 12.9B | |
| Low | 12.9B |
Revenue Growth
| Revenue Growth | 2027 | 2028 |
|---|---|---|
| High | 58.8% | |
| Avg | 58.8% | |
| Low | 58.8% |
EPS Forecast
| EPS | 2027 | 2028 |
|---|---|---|
| High | 40.00 | |
| Avg | 32.10 | |
| Low | 24.20 |
EPS Growth
| EPS Growth | 2027 | 2028 |
|---|---|---|
| High | 648.3% | |
| Avg | 500.5% | |
| Low | 352.7% |